RxDoctor Payments DataLook up a doctor →

Steven Kosa, MD

Neurology · North Kansas City, MONPI 1700895083

Payments from drug & device makers

$357,513in general payments, 2019–2025

Across 822 payments — averaging $434.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$115K
  • Lilly USA, LLC$56K
  • Pfizer$25K
  • Teva Pharmaceuticals USA, Inc.$23K
  • Eli Lilly$23K
  • Lundbeck LLC$20K
  • plus $94K from 54 others
$13,600in research payments, 2019–2025

Across 1 payment — averaging $13,600 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$14K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)213$115,224
Lilly USA, LLC137$55,988
Pfizer41$25,364
Teva Pharmaceuticals USA, Inc.39$23,486
Eli Lilly5$23,400
Lundbeck LLC60$20,095
Amgen25$19,370
Axsome Therapeutics, Inc.26$18,903
Biohaven Pharmaceutical Holding Company Ltd.14$16,581
H. Lundbeck A S2$11,000
Biohaven Pharmaceuticals, Inc.15$10,941
Impel Pharmaceuticals Inc.9$6,247
Ipsen Biopharmaceuticals, Inc4$4,689
Grifols USA, LLC3$1,552
Supernus Pharmaceuticals, Inc.48$411
Biogen11$362
Novartis15$316
ANI Pharmaceuticals, Inc.4$269
EMD Serono, Inc.10$228
Vanda Pharmaceuticals Inc.5$227
UCB, Inc.10$227
Tersera Therapeutics LLC7$179
Amneal Pharmaceuticals LLC7$145
Acadia Pharmaceuticals Inc8$141
Sanofi7$127
Argenx US, Inc.5$124
Jazz Pharmaceuticals Inc.5$108
CSL Behring4$105
Azurity Pharmaceuticals, Inc.5$101
Alnylam Pharmaceuticals Inc.5$88
Neurelis, Inc.3$83
Eisai Inc.4$81
Grifols Shared Services North America, Inc.1$77
Scilex Pharmaceuticals Inc.4$76
Sunovion Pharmaceuticals Inc.4$73
Adamas Pharmaceuticals, Inc.3$72
Otsuka America Pharmaceutical, Inc.3$67
Banner Life Sciences, LLC3$65
Genentech USA, Inc.3$65
Neurocrine Biosciences, Inc.3$60
Almatica Pharma LLC3$56
AstraZeneca3$53
SK Life Science, Inc.3$50
Abbott2$49
MDD US Operations, LLC3$49
Cycle Pharmaceuticals Inc2$42
Kyowa Kirin, Inc.2$38
Xeris Pharmaceuticals, Inc.2$34
Sumitomo Pharma America, Inc.2$29
Microtransponder, Inc.1$28
TG Therapeutics, Inc.1$27
Promius Pharma LLC1$25
Mallinckrodt Enterprises LLC1$23
GRT US Holding, Inc.1$23
C2n Diagnostics, LLC1$22
Catalyst Pharmaceuticals, Inc.1$22
Corium, LLC1$22
Merz Pharmaceuticals, LLC1$22
Hospira, Inc.1$20
Tanabe Pharma America, Inc.1$19

How this compares

$357,513 in reported general payments places this provider in the 90th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri →

Medicare billing

Part B allowed, 2024
$550,483
Medicare patients
289
Services billed
69,830

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in North Kansas City

See the full list for Missouri →

Where these figures come from

Is this you, or does something look wrong? →